To include your compound in the COVID-19 Resource Center, submit it here.

Merck reports earns in-line with expectations

Merck & Co. Inc. (NYSE:MRK) released on Friday 4Q17 figures, including sales of cancer drug Keytruda pembrolizumab, and 2018 guidance in line

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE